International Journal of Drug Delivery Technology
Volume 14, Issue 2

The Development of an Innovative Ophthalmic In-situ Gel Containing Posaconazole

Kumbhar ST1*, Salunke MA2, Mane PT3, Wakure BS2

1Department of Pharmaceutical Chemistry, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Maharashtra, India.

2Vilasrao Deshmukh Foundation, Group of Institutions, VDF School of Pharmacy, Latur, Maharashtra, India.

3Department of Pharmacy, Terna Public Charitable Trust’s College of Engineering, Dharashiv, Maharashtra, India. 

Received: 12th January, 2024; Revised: 18th March, 2024; Accepted: 20th May, 2024; Available Online: 25th June, 2024 

ABSTRACT

The goal of this study was to create and test various in-situ gel formulas for administering posaconazole to the eye to treat fungal keratitis. They used an in-situ gelling method to help posaconazole stay in the eye mucosa longer, which made it easier for the body to use. To make in-situ gel preparations, polymers such as sodium alginate, poloxamer 407, and poloxamer 188 were used in a cold method. Finally, there was 0.2% (w/w) posaconazole in the mixtures. The pH, drug content, viscosity, gelling capacity, and temperature at which the solution turns into a gel were all checked on the recipes. It was between 32 and 34℃ when each blend turned into a gel. There was about the same amount of drugs in all of them. It was also worked out how much of the antifungal and in-vitro drugs these mixtures would release. Everyone in the drug release study showed signs of long-lasting release. To sum up, in-situ gels that contain posaconazole could be a good way to use optical drug delivery to change how fungus diseases act.

Keywords: Ocular delivery, In-situ gel, Posaconazole, Corneal toxicity, Irritation testing. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.46

How to cite this article: Kumbhar ST, Salunke MA, Mane PT, Wakure BS. The Development of an Innovative Ophthalmic

In-situ Gel Containing Posaconazole. International Journal of Drug Delivery Technology. 2024;14(2):913-918.

REFERENCES

  1. Kouchak M. In Situ Gelling Systems for Drug Delivery. Jundishapur J Nat Pharm Prod. 2014;1;9(3):20126. https://doi. org/10.17795/jjnpp-20126
  2. Madan M, Bajaj A, Lewis S, Udupa N, Baig J. In situforming polymeric drug delivery systems. Indian J Pharm Sci. 2009;71(3):242. https://doi.org/10.4103/0250-474X.56015
  3. Nair AB, Shah J, Jacob S, Al-Dhubiab BE, Sreeharsha N, Morsy MA, et al. Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. PLoS ONE. 2021;19;16(3):e0248857. https://doi. org/10.1371/journal.pone.0248857
  4. Jacob S, Nair AB, Shah Emerging role of nanosuspensions in drug delivery systems. Biomater Res. 2020 Mar 20;24(1). https:// doi.org/10.1186/s40824-020-0184-8
  5. Madan M, Bajaj A, Lewis S, Udupa N, Baig J. In situforming polymeric drug delivery systems. Indian J Pharm Sci. 2009;71(3):242. https://doi.org/10.4103/0250-474X.56015
  6. Cao S, Ren X, Zhang Q, Chen E, Xu F, Chen J, et In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. International Journal of Pharmaceutics. 2009;5;365(1-2):109-15.. https://doi.org/10.1016/j. ijpharm.2008.08.042
  7. Chaudhary B, Verma S. Preparation and Evaluation of NovelIn SituGels Containing Acyclovir for the Treatment of Oral Herpes Simplex Virus The Scientific World Journal. 2014;2014:1-7. https://doi.org/10.1155/2014/280928
  8. Tamara Perchyonok V, Zhang S, Oberholzer T. Chitosan and Gelatin based Prototype Delivery Systems for the Treatment of Oral Mucositis: from Material to Performance in vitro. CDD. 2013;1;10(1):144-50. https://doi. org/10.2174/1567201811310010020
  9. Majeed A, & Khan Ocular in-situ gel: An overview. Journal of Drug Delivery and Therapeutics, 2019;9(1):337-347. https:// doi.org/10.22270/jddt.v9i1.
  10. Wang L, Zhou MB, Zhang H. The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye. Ophthalmol Ther. 2021;10(3):465-94. https://doi.org/10.1007/s40123-021- 00365-y
  11. Gupta, B., Mishra, V., Gharat, S., Momin, M., & Omri, A. (2021). Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems. Pharmaceuticals (Basel, Switzerland), 14(11), https://doi.org/10.3390/ph14111201
  12. Makwana S, Patel V, Parmar Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Results in Pharma Sciences. 2016;6:1-6.https:// doi.org/10.1016/j.rinphs.2015.06.001
  13. Wu Y, Liu Y, Li X, Kebebe D, Zhang B, Ren J, et al. Research progress of in-situ gelling ophthalmic drug delivery system. Asian Journal of Pharmaceutical Sciences. 2019;14(1):1-15. https://doi.org/10.1016/j. ajps.2018.04.008
  14. Bisht R, Mandal A, Jaiswal JK, Rupenthal ID. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases. WIREs Nanomed Nanobiotechnol. 2018;10(2).https://doi.org/10.1002/wnan.1473
  15. Joseph RR, Venkatraman Drug Delivery to the Eye: What Benefits do Nanocarriers offer? Nanomedicine (Lond). 2017;12(6):683-702. https://doi.org/10.2217/nnm-2016-0379
  16. Kotreka UK, Davis VL, Adeyeye MC. Development of topical ophthalmic In Situ gel-forming estradiol delivery system intended for the prevention of age-related cataracts. PLoS 2017;21;12(2):e0172306. https://doi.org/10.1371/journal. pone.0172306
  17. Destruel P, Zeng N, Seguin J, Douat S, Rosa F, Brignole-Baudouin F, et al. Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention International Journal of Pharmaceutics. 2020;574:118734. https://doi.org/10.1016/j. ijpharm.2019.118734
  18. Destruel P, Zeng N, Maury M, Mignet N, Boudy V. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond. Drug Discovery 2017;22(4):638-51. https://doi. org/10.1016/j. drudis.2016.12.008
  19. Gratieri T, Gelfuso GM, de Freitas O, Rocha EM, Lopez RF. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. European Journal of Pharmaceutics and Biopharmaceutics. 2011;79(2):320-7. https:// org/10.1016/j. ejpb.2011.05.006
  20. Sheshala R, Kok Y, Ng J, Thakur R, Dua K. In Situ Gelling Ophthalmic Drug Delivery System: An Overview and Its DDF. 2015;14;9(3):242-53. https://doi. org/10.2174/187221130 9666150724101227
  21. Kubo W, Konno Y, Miyazaki S, Attwood In Situ Gelling Pectin Formulations for Oral Sustained Delivery of Paracetamol. Drug Development and Industrial Pharmacy. 2004;30(6):593-9. https:// doi.org/10.1081/ddc-120037490
  22. Konatham M, gorle MT, et al. In situ gel polymers: a review. Int J App Pharm. 2021;13(1):86-90. https://doi.org/10.22159/ 2021v13i1.39504
  23. Prasanthi S, Vidyavathi M. Formulation and Optimization Of Buoyant In Situ Gelling System of Valsartan Using Natural Polymer. Int J Pharm Pharm Sci. 2017 Oct 2;9(10):128. https:// doi. org/10.22159/ijpps.2017v9i10.20809
  24. Nandgude TD. Emulgel: A Comprehensive Review for Topical Delivery of Hydrophobic Asian Journal of Pharmaceutics. 2018;12(02). https://doi.org/10.22377/ajp. v12i02.2366
  25. Soliman KA, Ullah K, Shah A, Jones DS, Singh Poloxamer- based in situ gelling thermoresponsive systems for ocular drug delivery applications. Drug Discovery Today. 2019;24(8):1575-86. https://doi.org/10.1016/j.drudis.2019.05.036
  26. Fakhari A, Corcoran M, Schwarz A. Thermogelling properties of purified poloxamer 407. Heliyon. 2017;3(8):e00390. https:// org/10.1016/j.heliyon.2017.e00390
  27. Al Khateb K, Ozhmukhametova EK, Mussin MN, Seilkhanov SK, Rakhypbekov TK, Lau WM, et al. In situ gelling systems
  28. based on Pluronic F127/Pluronic F68 formulations for ocular drug International Journal of Pharmaceutics. 2016 ;502(1- 2):70-9. https://doi.org/10.1016/j.ijpharm.2016.02.027
  29. Krtalić I, Radošević S, Hafner A, Grassi M, Nenadić M, Cetina-Čižmek B, et al. D-Optimal Design in the Development of Rheologically Improved In Situ Forming Ophthalmic Gel. Journal of Pharmaceutical Sciences. 2018 Jun;107(6):1562-71. https:// doi.org/10.1016/j.xphs.2018.01.019
  30. Moloughney GJ, Weisleder Poloxamer 188 ( P188) as a Membrane Reseali ng Reagent i n Biomedical Ap pl icat ion s . BIOT. 2012 ; 6 (3): 20 0 -11. ht t ps://doi. org/10.2174/1872208311206030200
  31. Waddell LB, Lemckert FA, Zheng XF, Tran J, Evesson FJ, Hawkes JM, et Dysferlin, Annexin A1, and Mitsugumin 53 Are Upregulated in Muscular Dystrophy and Localize to Longitudinal Tubules of the T-System With Stretch. J Neuropathol Exp Neurol. 2011;70(4):302-13. https://doi. org/10.1097/NEN.0b013e31821350b0
  32. Aykaç K, Yenilmez E, et . Posaconazole loaded ocular inserts for antifungal activity. Journal of Pharmaceutical Technology. 2020;1(1):1-6.
  33. Chaudhari P, Ghate VM, Lewis Supramolecular cyclodextrin complex: Diversity, safety, and applications in ocular therapeutics. Experimental Eye Research. 2019;189:107829. https://doi. org/10.1016/j. exer.2019.107829
  34. Franca JR, Foureaux G, Fuscaldi LL, Ribeiro TG, Castilho RO, Yoshida MI, et al. Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation. International Journal of Pharmaceutics. 2019;570:118662. https://doi.org/10.1016/j.ijpharm.2019.118662
  35. Mohammed BS, Al-Gawhari FJ. Preparation of Posaconazole Nanosponges for Improved Topical Delivery System. International Journal of Drug Delivery Technology. 2022;12(1):8-14.
  36. Greer ND. Posaconazole (Noxafil): A New Triazole Antifungal Agent. Baylor University Medical Center 2007;20(2):188-96. https://doi.org/10.1080/08998280.2007.11928283
  37. Nasser ST, Abdulrassol AA, Ghareeb Design, Preparation, and In-vitro Evaluation of Novel Ocular Antifungal Nanoemulsion Using Posaconazole as a Model Drug. International Journal of Drug Delivery Technology. 2021;11(3):1058-1064.
  38. Sengupta J, Saha S, Banerjee D, Khetan A. Epidemiological profile of fungal keratitis in urban population of West Bengal, India. Oman J Ophthalmol. 2009;2(3):114. https://doi. org/10.4103/0974-620X.57310
  39. Klont RR, Eggink CA, Rijs AJMM, Wesseling P, Verweij PE. Successful Treatment of Fusarium Keratitis with Cornea Transplantation and Topical and Systemic Voriconazole. Clinical Infectious Diseases. 2005;40(12):e110-e112. https:// doi. org/10.1086/430062